Get started
Author

Keith A. Lerro

Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402
2009 · Rogerio Lilenbaum, Xiaofei Wang, et al. · Journal of Clinical Oncology · 42
PDF
A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents
2003 · K A Lerro, E Medoff, et al. · Bone Marrow Transplantation · 26
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
2021 · Maen Hussein, Marina Maglakelidze, et al. · Cancer Management and Research · 25
PDF
Assessing the Validity of Tuberculin Skin Test Readings by Trained Professionals and Patients
1999 · Philip O. Ozuah, William Burton, et al. · CHEST Journal · 21
Case Report: A Patient with Primary CNS Lymphoma Treated with Temozolomide to Complete Response
2002 · Keith A. Lerro, Jill Lacy · Journal of Neuro-Oncology · 14
Abstract 648: Activity of BNT327/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327 + ADC combinations
2025 · Erika P. Hamilton, Jianqing Zhu, et al. · Cancer Research · 4
MO01.42 Myelopreservation with Trilaciclib Regardless of Risk of Chemotherapy-Induced Febrile Neutropenia and/or Anemia or Red Blood Cell Transfusions
2021 · M. Hussein, T.A. Gersten, et al. · Journal of Thoracic Oncology · 1
PDF
Abstract LB207: Continuous subcutaneous lenalidomide delivery improves the therapeutic index and avoids drug-related grade 3/4 hematologic toxicity in patients with relapsed/refractory multiple myeloma
2025 · Nash Gabrail, Keith Lerro, et al. · Cancer Research
Works count: 8
Citation count: 133
H-index: 5
I10-index: 5
Year
Topic
Type